Meeder Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Meeder Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5	Closed	–	–	2430
2021 Q4	$0	Buy	+5	New	+$12	﹤0.01%	1794
2018 Q4	–	Sell	-2,029	Closed	-$4K	–	1757
2018 Q3	$4K	Buy	+2,029	New	+$4.26K	﹤0.01%	1368
2018 Q1	–	Sell	-162	Closed	–	–	1649
2017 Q4	$0	Buy	+162	New	+$354	﹤0.01%	1728
2017 Q3	–	Sell	-253	Closed	-$1K	–	1699
2017 Q2	$1K	Sell	253 -749	-75%	-$2.09K	﹤0.01%	1526
2017 Q1	$3K	Buy	+1,002	New	+$2.85K	﹤0.01%	1264

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Meeder Asset Management's LCTX Position: Q1 2022 in Review

Meeder Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 5 shares.

Meeder Asset Management first reported a position in LCTX in Q1 2017 and held it in 5 quarters. The position peaked at $4K in Q3 2018. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

Meeder Asset Management reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
Meeder Asset Management sold 5 Lineage Cell Therapeutics shares in Q1 2022.
Meeder Asset Management first reported a position in Lineage Cell Therapeutics in Q1 2017 and held it in 5 quarters.
Meeder Asset Management's Lineage Cell Therapeutics position peaked at $4K in Q3 2018.
110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on Meeder Asset Management's 13F filing for Q1 2022, filed 10 May 2022.